Author/Authors :
Safarnezhad Tameshkel , Fahimeh Gastrointestinal and Liver Diseases Research Center - Iran University of Medical Sciences, Tehran, Iran , Karbalaie Niya, Mohammad Hadi Gastrointestinal and Liver Diseases Research Center - Iran University of Medical Sciences, Tehran, Iran , Khoonsari, Mahmoodreza Gastrointestinal and Liver Diseases Research Center - Iran University of Medical Sciences, Tehran, Iran , Ajdarkosh , Hossein Gastrointestinal and Liver Diseases Research Center - Iran University of Medical Sciences, Tehran, Iran , Faraji , Amir Hossein Gastrointestinal and Liver Diseases Research Center - Iran University of Medical Sciences, Tehran, Iran , Nikkhah, Mehdi Gastrointestinal and Liver Diseases Research Center - Iran University of Medical Sciences, Tehran, Iran , Motamed , Nima Department of Social Medicine - Zanjan University of Medical Sciences, Zanjan, Iran , Azarkeivan, Azita Pediatric Hematology Oncology - Blood Transfusion Research Center - High Institute for Research and Education in Transfusion Medicine -Thalassemia Clinic, Tehran, Ira , Gholami, Ali Non-communicable Diseases Research Center - Neyshabur University of Medical Sciences, Neyshabur, Iran , Sohrabi, Masood Reza Gastrointestinal and Liver Diseases Research Center - Iran University of Medical Sciences, Tehran, Iran , Keyvani , Hossein Department of Virology - Iran University of Medical Sciences, Tehran, Iran , Zamani, Farhad Gastrointestinal and Liver Diseases Research Center - Iran University of Medical Sciences, Tehran, Iran
Abstract :
BACKGROUND
Direct-acting antivirals (DAAs) against hepatitis C virus (HCV) infection showed
the presence of resistant-associated substitutions (RASs). The aim of the present study
was to carry out a follow-up of patients with baseline RASs to report the impact of
RASs on DAA therapy outcome.
METHODS
In a cohort study, we analyzed NS5A and NS5B RASs among nine thalassemia cases
by baseline RASs. In a 2-year follow-up, we analyzed viral markers and biochemical
and hematological parameters of the participants and their sustained virologic response
(SVR). Statistical analyses were performed using SPSS software version 22.
RESULTS
RASs for HCV subtype 1a included M28V, L31M, and H58P. For subtype 1b: L28M,
R30Q, S24F, and C316N. and for subtype 3a: C316S, and S24F. In patients with cirrhosis
(n = 5), ALT (p = 0.001) and AST (p = 0.007) levels were significantly reduced after
treatment, and creatinine level slightly increased (p = 0.025). However, no significant
data was observed in non-cirrhotic patients following the treatment.
CONCLUSION
The present study did not show any adverse effects of DAA therapy among patients
with thalassemia suffering from chronic HCV infection with baseline RASs. Furthermore,
reduction in ferritin and liver stiffness levels after DAA therapy could show the efficacy
of DAA in such patients.
